IMMUNE PHARMACEUTICALS INC — Operating Income by Fiscal Year
9 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/369da9da-eda9-4626-a800-e67a22668f1f/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2017 | $-12.1M | 2017-01-01 – 2017-12-31 | evidence 0001144204-18-018699 |
| FY 2016 | $-27.3M | 2016-01-01 – 2016-12-31 | evidence 0001144204-17-028202 |
| FY 2015 | $-15.7M | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-091621 |
| FY 2014 | $-16.4M | 2014-01-01 – 2014-12-31 | evidence 0001144204-15-023077 |
| FY 2013 | $-23.8M | 2010-07-11 – 2014-03-31 | evidence 0001437749-14-009586 |
| FY 2012 | $-9.2M | 2012-01-01 – 2012-12-31 | evidence 0001437749-14-006363 |
| FY 2011 | $-14.1M | 2011-01-01 – 2011-12-31 | evidence 0001104659-12-022842 |
| FY 2010 | $-15.4M | 2010-01-01 – 2010-12-31 | evidence 0001104659-12-022842 |
| FY 2009 | $-18.7M | 2009-01-01 – 2009-12-31 | evidence 0001104659-12-022842 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
IMMUNE PHARMACEUTICALS INC — all facts · Revenue · Net Income